A Phase 4 Randomized OpenLabel Trial to Describe the Safety Tolerability and Immunogenicity of 13 Valent Pneumococcal Conjugate Vaccine Formulated in Multidose Vials When Given With Routine Pediatric Vaccines in Healthy Infants in India.

Trial Profile

A Phase 4 Randomized OpenLabel Trial to Describe the Safety Tolerability and Immunogenicity of 13 Valent Pneumococcal Conjugate Vaccine Formulated in Multidose Vials When Given With Routine Pediatric Vaccines in Healthy Infants in India.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 30 Jan 2018 Planned initiation date changed from 21 Nov 2017 to 2 Apr 2018.
    • 12 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top